Tungstate Treatment Of The Dysbiosis Associated With Gastrointestinal Inflammation

Abstract

The present invention provides compositions of therapeutic agents and methods of use for reducing and/or treating gastrointestinal inflammation. In particular aspects, the tungstate salts described herein and pharmaceutical compositions thereof inhibit the activity of one or a plurality of anaerobic respiratory enzymes in facultative anaerobic bacteria such as, for example, Enterobacteriaceae, that can exacerbate inflammation. In particular embodiments, the present invention provides compositions of therapeutic agents for treating gastrointestinal inflammation, as well as methods for treating or preventing gut microbial imbalance due to an increase in the abundance of intestinal Enterobacteriaceae.


Claims
Download PDF
Document Preview
Document History
  • Publication: Oct 9, 2018
  • Application: Dec 9, 2015
    US US 201514964487 A
  • Priority: Dec 9, 2015
    US US 201514964487 A
  • Priority: Jun 9, 2014
    US US 2014/0041571 W
  • Priority: Jun 10, 2013
    US US 201361833396 P

Download Citation


Sign in to the Lens

Feedback